Lin Xue-Jing, Tang Er-Jiang, Sun Bin, Wang Ai-Li, Chen Ying, Chen Lei, Xue Yi-Yang, Li A-Jian, Liu Chun-Ying
Center for Clinical Research and Translational Medicine, Yangpu Hospital, Tongji University School of Medicine, Shanghai 200090, China.
National Center for Liver Cancer, Naval Medical University, Shanghai 201805, China.
World J Gastrointest Oncol. 2025 Jul 15;17(7):107971. doi: 10.4251/wjgo.v17.i7.107971.
BACKGROUND: Metabolic dysregulation is considered a significant hallmark of hepatocellular carcinoma (HCC). SAC3 domain containing 1 (SAC3D1) functions in the cell cycle, and its expression is upregulated in various cancers. It is known that metabolic changes occur at different stages of the cell cycle to maintain the biosynthesis and replication of both normal and cancer cells. Based on the role of SAC3D1 in mitosis, we hypothesize that abnormal expression of SAC3D1 may affect cellular metabolism. However, it remains unclear whether SAC3D1 mediates the progression of HCC by regulating metabolic reprogramming. AIM: To comprehensively elucidate the impact and molecular mechanism of SAC3D1 on the progression of HCC by regulating the metabolic reprogramming. METHODS: The constructed SAC3D1 overexpression and knockdown HCC cell lines were used for detecting cell proliferation, migration capabilities, as well as glycolysis and adenosine triphosphate (ATP) production rate assays. They were also employed for examining molecular markers associated with cell migration and glycolysis. The transcriptome sequencing data of cells have revealed the pathways potentially influenced by SAC3D1.The tail vein metastasis model and xenograft tumor experiments were utilized to demonstrate SAC3D1's tumor-promoting effects . RESULTS: SAC3D1 expression was upregulated and associated with poor prognosis in HCC patients. SAC3D1 enhanced the proliferation and migration abilities and reduced the population dependence of HCC cells and . The upregulation of SAC3D1 enhanced cellular glycolysis and ATP production. The cell transcriptome sequencing data revealed that SAC3D1 activated Wnt signaling pathway. SAC3D1 did not modulate the transcription of , while might inhibit its degradation. Further investigations indicated that the increase of SAC3D1 leads to more β-Catenin accumulating in the nucleus, facilitating the expression of c-Myc, one of the upstream regulatory factors of glycolysis. The iCRT3, an antagonist of β-Catenin, could counteract the increase of c-Myc induced by SAC3D1, while also downregulating the expression of glycolysis-related proteins. CONCLUSION: This study found that SAC3D1 enhances HCC cell glycolysis and ATP production the β-Catenin/c-Myc signaling axis, thereby promoting the progression of HCC.
背景:代谢失调被认为是肝细胞癌(HCC)的一个重要标志。含SAC3结构域蛋白1(SAC3D1)在细胞周期中发挥作用,其在多种癌症中表达上调。已知在细胞周期的不同阶段会发生代谢变化,以维持正常细胞和癌细胞的生物合成及复制。基于SAC3D1在有丝分裂中的作用,我们推测SAC3D1的异常表达可能影响细胞代谢。然而,SAC3D1是否通过调节代谢重编程介导HCC的进展仍不清楚。 目的:通过调节代谢重编程全面阐明SAC3D1对HCC进展的影响及分子机制。 方法:使用构建的SAC3D1过表达和敲低的HCC细胞系检测细胞增殖、迁移能力以及糖酵解和三磷酸腺苷(ATP)产生率测定。它们还用于检测与细胞迁移和糖酵解相关的分子标志物。细胞转录组测序数据揭示了可能受SAC3D1影响的通路。利用尾静脉转移模型和异种移植肿瘤实验来证明SAC3D1的促肿瘤作用。 结果:SAC3D1在HCC患者中表达上调且与预后不良相关。SAC3D1增强了HCC细胞的增殖和迁移能力,并降低了细胞群体依赖性。SAC3D1的上调增强了细胞糖酵解和ATP产生。细胞转录组测序数据显示SAC3D1激活了Wnt信号通路。SAC3D1未调节[具体基因]的转录,而可能抑制其降解。进一步研究表明,SAC3D1的增加导致更多β-连环蛋白在细胞核中积累,促进了糖酵解上游调节因子之一c-Myc的表达。β-连环蛋白拮抗剂iCRT3可以抵消SAC3D1诱导的c-Myc增加,同时也下调糖酵解相关蛋白的表达。 结论:本研究发现SAC3D1通过β-连环蛋白/c-Myc信号轴增强HCC细胞糖酵解和ATP产生,从而促进HCC进展。
World J Gastrointest Oncol. 2025-7-15
J Hepatocell Carcinoma. 2025-7-10
Cell Commun Signal. 2024-6-6
Cancer Cell. 2024-2-12
Front Pharmacol. 2023-3-21
Cancer Metastasis Rev. 2023-9
Mol Med Rep. 2022-10
Trends Endocrinol Metab. 2022-7